CHRM1 and neoplasm: demonstrated that activation of cholinergic signaling activation suppresses cancer stemness and tumor growth in genetically engineered PDAC models through CHRM1‐mediated inhibition of both the MAPK/EGFR and PI3K/AKT pathways [114].